Cancer Pharmacology and Computational Medicine
At Cancer Pharmacology and Computational Medicine we combine high-throughput screening, drug repurposing, innovative cell models, primary patient derived cells and computational approaches to find new treatment alternatives.
Description of our research
The research carried out in the research group is mainly focused on aspects of drugs being used in cancer treatments.
Group members
Publications
Comparison of high-throughput single-cell RNA-seq methods for ex vivo drug screening
Part of NAR Genomics and Bioinformatics, 2024
Tumor-specific migration routes of xenotransplanted human glioblastoma cells in mouse brain
Part of Scientific Reports, 2024
Part of Journal of clinical pharmacology, p. 240-252, 2024
Enrichment of thawed boar spermatozoa with an intact membrane using Magnetic Activated Cell Sorting
Part of Animal Reproduction Science, 2024
Part of BMC Palliative Care, 2024
- DOI for Fluid therapy is associated with lower care quality and higher symptom burden during last days of life of patients with cancer: - a population-based register study
- Download full text (pdf) of Fluid therapy is associated with lower care quality and higher symptom burden during last days of life of patients with cancer: - a population-based register study
OCT1 (SLC22A1) transporter kinetics and regulation in primary human hepatocyte 3D spheroids
Part of Scientific Reports, 2024
Part of BMC Pharmacology & Toxicology, 2024
Part of Anti-Cancer Drugs, p. 92-102, 2023
Part of Scientific Reports, 2023
Part of ESMO Open, 2023
Part of Clinical Cancer Research, p. 2826-2834, 2023
Disease phenotype prediction in multiple sclerosis
Part of iScience, 2023
Aminopeptidases in Cancer, Biology and Prospects for Pharmacological Intervention
Part of Current Cancer Drug Targets, p. 25-46, 2023
Part of Journal of Autoimmunity, 2023
- DOI for Extracellular vesicles opsonized by monomeric C-reactive protein (CRP) are accessible as autoantigens in patients with systemic lupus erythematosus and associate with autoantibodies against CRP
- Download full text (pdf) of Extracellular vesicles opsonized by monomeric C-reactive protein (CRP) are accessible as autoantigens in patients with systemic lupus erythematosus and associate with autoantibodies against CRP
Part of Cardiovascular Toxicology, p. 255-264, 2023
- DOI for Electronic Cigarette Vaping with Nicotine Causes Increased Thrombogenicity and Impaired Microvascular Function in Healthy Volunteers: A Randomised Clinical Trial
- Download full text (pdf) of Electronic Cigarette Vaping with Nicotine Causes Increased Thrombogenicity and Impaired Microvascular Function in Healthy Volunteers: A Randomised Clinical Trial
Part of Reproduction in domestic animals, p. 1569-1575, 2023
- DOI for Evaluation of domestic animal sperm head morphology via flow cytometric DNA labelling and pulse shape analysis using bull and stallion spermatozoa as model species
- Download full text (pdf) of Evaluation of domestic animal sperm head morphology via flow cytometric DNA labelling and pulse shape analysis using bull and stallion spermatozoa as model species
Managing leukemia patients via liquid biopsy and super rolling circle amplification (superRCA)
Part of Journal of Internal Medicine, p. 228-237, 2023
Part of Clinical Cancer Research, p. 4139-4152, 2023
- DOI for Single-Cell RNA Analysis Reveals Cell-Intrinsic Functions of CAR T Cells Correlating with Response in a Phase II Study of Lymphoma Patients
- Download full text (pdf) of Single-Cell RNA Analysis Reveals Cell-Intrinsic Functions of CAR T Cells Correlating with Response in a Phase II Study of Lymphoma Patients
Preclinical tumor-immune modeling: For the identification of immunomodulatory drugs
2023
Part of BMC Cancer, 2023
Part of International Journal of Oncology, 2022
- DOI for Ex vivo assessment of cancer drug sensitivity in epithelial ovarian cancer and its association with histopathological type, treatment history and clinical outcome
- Download full text (pdf) of Ex vivo assessment of cancer drug sensitivity in epithelial ovarian cancer and its association with histopathological type, treatment history and clinical outcome
Part of NATURE CANCER, p. 156, 2022
Quiescent cancer cells: Three-dimensional cell models for evaluation of new therapeutics
2022
Immune-Proteome Profiling in Classical Hodgkin Lymphoma Tumor Diagnostic Tissue
Part of Cancers, 2022
Part of Pain, p. 1999-2013, 2022
Selective radiosensitization by nitazoxanide of quiescent clonogenic colon cancer tumour cells
Part of Oncology Letters, 2022
Part of European Urology Open Science, p. 38-45, 2022
- DOI for Ilixadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma: A Randomized Phase 2 Study
- Download full text (pdf) of Ilixadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma: A Randomized Phase 2 Study
Part of Nature Communications, 2022
- DOI for Cell-lineage controlled epigenetic regulation in glioblastoma stem cells determines functionally distinct subgroups and predicts patient survival
- Download full text (pdf) of Cell-lineage controlled epigenetic regulation in glioblastoma stem cells determines functionally distinct subgroups and predicts patient survival
Part of Scientific Reports, 2022
- DOI for Sorafenib and nitazoxanide disrupt mitochondrial function and inhibit regrowth capacity in three-dimensional models of hepatocellular and colorectal carcinoma
- Download full text (pdf) of Sorafenib and nitazoxanide disrupt mitochondrial function and inhibit regrowth capacity in three-dimensional models of hepatocellular and colorectal carcinoma
Surgical waiting times and all-cause mortality in patients with non-metastatic renal cell carcinoma
Part of Scandinavian journal of urology, p. 383-390, 2022
Part of New Biotechnology, p. 21-29, 2022
Single-cell transcriptional pharmacodynamics of trifluridine in a tumor-immune model
Part of Scientific Reports, 2022
Metabolomics: The Stethoscope for the Twenty-First Century
Part of Medical principles and practice, p. 301-310, 2021
Multi‐cohort profiling reveals elevated CSF levels of brain‐enriched proteins in Alzheimer’s disease
Part of Annals of Clinical and Translational Neurology, p. 1456-1470, 2021
Part of Journal of Alzheimer's Disease, p. 629-640, 2021
Melphalan flufenamide inhibits osteoclastogenesis by suppressing proliferation of monocytes
Part of Bone Reports, 2021
Part of Cytokine, 2021
Conditions for maintenance of hepatocyte differentiation and function in 3D cultures
Part of iScience, 2021
Part of Genes, 2021
Part of Scientific Reports, 2021
- DOI for A phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer
- Download full text (pdf) of A phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer
Part of Blood Advances, p. 1003-1016, 2021
Plasma proteome profiling of cardiotoxicity in patients with diffuse large B-cell lymphoma
Part of Cardio-Oncology, 2021
Metabolic drift in the aging nervous system is reflected in human cerebrospinal fluid
Part of Scientific Reports, 2021
Toll-like receptor 4 methylation grade is linked to depressive symptom severity
Part of Translational Psychiatry, 2021
Part of F1000 Research, p. 513-513, 2021
Part of Trials, 2021
- DOI for COVIDENZA - A prospective, multicenter, randomized PHASE II clinical trial of enzalutamide treatment to decrease the morbidity in patients with Corona virus disease 2019 (COVID-19): a structured summary of a study protocol for a randomised controlled trial
- Download full text (pdf) of COVIDENZA - A prospective, multicenter, randomized PHASE II clinical trial of enzalutamide treatment to decrease the morbidity in patients with Corona virus disease 2019 (COVID-19): a structured summary of a study protocol for a randomised controlled trial
Mebendazole is unique among tubulin-active drugs in activating the MEK-ERK pathway
Part of Scientific Reports, 2020
Targeting aggressive osteosarcoma with a peptidase-enhanced cytotoxic melphalan flufenamide
Part of THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020
2020
Part of PLOS ONE, 2020